ALTITUDE: New Data on Why Trial Halted

The renin inhibitor aliskiren showed no benefit when added to ACE-inhibitor/ARB treatment in diabetic patients at high cardiovascular and renal risk and increased the risk of stroke and hyperkalemia.

Heartwire

via Medscape news